NEW YORK, May 25, 2017 /PRNewswire/ --
Stock-Callers.com revisits the Healthcare sector, which is an aggregationand integration of sectors within the economic system that provides goods and services to treat patients with curative, preventive, rehabilitative, and palliative care. Lined up for evaluation this morning are the following four stocks: Pfizer Inc. (NYSE:
On Wednesday, shares in New York headquartered Pfizer Inc. recorded a trading volume of 22.44 million shares, which was higher than their three months average volume of 22.22 million shares. The stock ended at $32.05, declining 0.28% from the last trading session. The Company's shares are trading below their 200-day moving average by 3.46%. Furthermore, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 22.41.
On May 16th, 2017, research firm Citigroup downgraded the Company's stock rating from 'Neutral' to 'Sell'.
On May 17th, 2017, Pfizer announced it will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 mechanisms of action, at the 53rd Annual Meeting of the American Society of Clinical Oncology in Chicago from June 02nd, 2017, to June 06th, 2017. New data will be featured in nine, oral presentations from company-sponsored clinical trials. Access our complete research report on PFE for free at:
Parsippany, New Jersey headquartered Zoetis Inc.'s stock finished yesterday's session 1.42% higher at $62.30. A total volume of 3.87 million shares was traded, which was above their three months average volume of 3.10 million shares. The Company's shares have gained 13.03% in the last one month, 16.27% over the previous three months, and 16.38% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.90% and 17.74%, respectively. Furthermore, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have an RSI of 79.64.
On May 11th, 2017, Zoetis' Board of Directors has declared a Q3 2017 dividend payable to holders of the Company's common stock of $0.105 per share. The dividend is to be paid on Friday, September 01st, 2017, to holders of record on Thursday, June 15th, 2017. The complimentary research report on ZTS can be downloaded at:
At the close of trading on Wednesday, shares in Chesterfield, the UK-based Mallinckrodt PLC rose 0.95%, ending the day at $40.24. The stock recorded a trading volume of 2.12 million shares, which was above its three months average volume of 1.87 million shares. The Company's shares are trading 10.16% below their 50-day moving average. Moreover, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, the Middle East, Africa, and internationally, have an RSI of 33.34.
On May 09th, 2017, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $91 a share to $87 a share.
On May 23rd, 2017, Mallinckrodt confirmed enrollment of the first patient in its Phase-4 pilot study assessing the efficacy of H.P. Acthar® Gel (repository corticotropin injection) for the management of exacerbations of relapsing and remitting multiple sclerosis in patients, whose relapse symptoms have not responded to a course of high-dose corticosteroids. Register for free on Stock-Callers.com and get access to the latest PDF format report on MNK at:
Amsterdam, the Netherlands-based Patheon N.V.'s shares ended the day 0.23% higher at $34.68 with a total trading volume of 1.04 million shares. The stock has gained 36.00% in the last month, 6.81% over the previous three months, and 20.79% on an YTD basis. The Company's shares are trading 25.39% above their 50-day moving average and 22.79% above their 200-day moving average. Additionally, shares of Patheon, which provides outsourced pharmaceutical development and manufacturing services, have an RSI of 82.65.
On May 08th, 2017, Patheon announced that it has completed an expansion project at its Greenville, NC manufacturing site. The Company invested approximately $26 million to update one of its sterile Pharmaceutical Development Services (PDS) suites and to build a state-of-the-art, fully integrated sterile PDS suite, which are compliant with regulatory authorities. The PDS Suites 1 and 2 provide 7,000-square-feet in GMP sterile manufacturing space.
On May 16th, 2017, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'. Download your free research report on PTHN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All